ANDRES MANUEL R
CERVANTES RUIPEREZ
CATEDRÁTICO/A DE UNIVERSIDAD
Hospital de la Santa Creu i Sant Pau
Barcelona, EspañaPublicacions en col·laboració amb investigadors/es de Hospital de la Santa Creu i Sant Pau (15)
2021
-
Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project
European Journal of Surgical Oncology, Vol. 47, Núm. 2, pp. 276-284
2017
-
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX
European Journal of Cancer, Vol. 82, pp. 16-24
2015
-
FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: An international consortium study
Gut, Vol. 64, Núm. 6, pp. 921-928
2012
-
First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Onkologie, Vol. 6, Núm. 2, pp. 96-103
-
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Oncologist, Vol. 17, Núm. 1, pp. 15-25
-
Role of Kras Status in Patients with Metastatic Colorectal Cancer Receiving First-Line Chemotherapy plus Bevacizumab: A TTD Group Cooperative Study
PLoS ONE, Vol. 7, Núm. 10
2010
-
Advanced ovarian cancer: Phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel
Journal of the National Cancer Institute, Vol. 102, Núm. 20, pp. 1547-1556
2007
-
Treatment guidelines in ovarian cancer
Clinical and Translational Oncology, Vol. 9, Núm. 5, pp. 308-316
2005
-
Two consecutive phase II trials of biweekly oxaliplatin plus weekly 48-hour continuous infusion of nonmodulated high-dose 5-fluorouracil as first-line treatment for advanced colorectal cancer
Clinical Colorectal Cancer, Vol. 4, Núm. 6, pp. 384-389
2004
-
Phase I/II trial of irinotecan plus high-dose 5-fluorouracil (TTD regimen) as first-line chemotherapy in advanced colorectal cancer
Annals of Oncology, Vol. 15, Núm. 4, pp. 559-567
2003
-
Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: A high proportion of mutations unique to Spain and evidence of founder effects
Human Mutation, Vol. 22, Núm. 4, pp. 301-312
-
Irinotecan (CPT-11) in Metastatic Colorectal Cancer Patients Resistant to 5-Fluorouracil (5-FU): A Phase II Study
Methods and Findings in Experimental and Clinical Pharmacology, Vol. 25, Núm. 8, pp. 639-643
2000
-
Two consecutive studies using oral UFT-based chemotherapy regimens in elderly patients with advanced colorectal cancer
Clinical and Translational Oncology, Vol. 2, Núm. 3, pp. 154-158
1999
-
UFT Plus or Minus Calcium Folinate for Metastatic Golorectal Cancer in Older Patients
ONCOLOGY, Vol. 13, Núm. 7 SUPPL., pp. 35-40